182 related articles for article (PubMed ID: 10443186)
1. Pediatric drug studies. Protecting pint-sized patients.
Nordenberg T
FDA Consum; 1999; 33(3):23-8. PubMed ID: 10443186
[No Abstract] [Full Text] [Related]
2. Paediatric clinical trials: redressing the imbalance.
Schreiner MS
Nat Rev Drug Discov; 2003 Dec; 2(12):949-61. PubMed ID: 14654794
[No Abstract] [Full Text] [Related]
3. New pediatric dosage rules: information and testing.
Feeg VD
Pediatr Nurs; 1998; 24(6):518, 613. PubMed ID: 10085992
[No Abstract] [Full Text] [Related]
4. Pediatric study of medicines becomes mandatory.
Bonetta L
Nat Med; 2000 Oct; 6(10):1069. PubMed ID: 11017118
[No Abstract] [Full Text] [Related]
5. Ethical implications of pediatric drug research policy initiatives.
Twomey JG
IRB; 2000; 22(2):5-10. PubMed ID: 11883466
[No Abstract] [Full Text] [Related]
6. Improving pediatric dosing through pediatric initiatives: what we have learned.
Rodriguez W; Selen A; Avant D; Chaurasia C; Crescenzi T; Gieser G; Di Giacinto J; Huang SM; Lee P; Mathis L; Murphy D; Murphy S; Roberts R; Sachs HC; Suarez S; Tandon V; Uppoor RS
Pediatrics; 2008 Mar; 121(3):530-9. PubMed ID: 18310202
[TBL] [Abstract][Full Text] [Related]
7. "Getting the dose right": facts, a blueprint, and encouragements.
Peck CC; Cross JT
Clin Pharmacol Ther; 2007 Jul; 82(1):12-4. PubMed ID: 17571068
[No Abstract] [Full Text] [Related]
8. The march toward rational therapeutics in children.
Gorman RL
Pediatr Infect Dis J; 2003 Dec; 22(12):1119-23. PubMed ID: 14688584
[TBL] [Abstract][Full Text] [Related]
9. Microdosing Studies in Children: A US Regulatory Perspective.
Roth-Cline M; Nelson RM
Clin Pharmacol Ther; 2015 Sep; 98(3):232-3. PubMed ID: 26095312
[TBL] [Abstract][Full Text] [Related]
10. US court rules to allow experimental drugs for dying patients.
Waltz E
Nat Med; 2006 Jun; 12(6):596. PubMed ID: 16760988
[No Abstract] [Full Text] [Related]
11. To market, to market. The nuts and bolts of prescription drug approval.
Peterson AM
Adv Nurse Pract; 2001 Apr; 9(4):87-90. PubMed ID: 12420443
[No Abstract] [Full Text] [Related]
12. A stepwise approach to evaluating new drug therapy.
Wessell A; Blair M
JAAPA; 2001 Nov; 14(11):10-1. PubMed ID: 11766421
[No Abstract] [Full Text] [Related]
13. Dying to live.
Nat Med; 2006 Jun; 12(6):593. PubMed ID: 16760985
[No Abstract] [Full Text] [Related]
14. FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma.
Cohen MH; Johnson JR; Justice R; Pazdur R
Oncologist; 2008 Jun; 13(6):709-14. PubMed ID: 18586926
[TBL] [Abstract][Full Text] [Related]
15. Institute of Medicine's new drug safety report: implications for Canada.
Cassels A
CMAJ; 2006 Dec; 175(12):1515-6. PubMed ID: 17146086
[No Abstract] [Full Text] [Related]
16. The seduction of biomarkers in the practice of medicine and the tyranny of power in the drug approval process: lessons from niacin.
Lehmann DF; Sitar DS
J Clin Pharmacol; 2011 Nov; 51(11):1496-8. PubMed ID: 21998350
[No Abstract] [Full Text] [Related]
17. Pediatric clinical trials: shall we take a lead?
Schreiner MS; Greeley WJ
Anesth Analg; 2002 Jan; 94(1):1-3. PubMed ID: 11772791
[No Abstract] [Full Text] [Related]
18. Pediatric drug development in anesthesiology: an FDA perspective.
Schultheis LW; Mathis LL; Roca RA; Simone AF; Hertz SH; Rappaport BA
Anesth Analg; 2006 Jul; 103(1):49-51. PubMed ID: 16790624
[No Abstract] [Full Text] [Related]
19. Adolescents in clinical trials.
Kapogiannis BG; Mattison DR
Clin Pharmacol Ther; 2008 Dec; 84(6):655-9. PubMed ID: 19008903
[TBL] [Abstract][Full Text] [Related]
20. Prescription for trouble: common drugs, hidden dangers. Tens of people are at risk.
Consum Rep; 2006 Jan; 71(1):34-9. PubMed ID: 16491527
[No Abstract] [Full Text] [Related]
[Next] [New Search]
